info icon

This is a non-core endpoint: only basic statistics are computed.

See these related core endpoints for full statistics:

Use of levodopa decarboxylase inhibitor

PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

No definition available.

Endpoint definition

↥
FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Medicine purchases: ATC N04BA02

1 out of 7 registries used, show all original rules.

3470

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

3470

diagram downward connector

Include endpoints None

3470

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

3388

diagram downward connector
PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 3388 1338 2050
Unadjusted prevalence (%) 0.90 0.63 1.23
Mean age at first event (years) 69.15 67.96 69.93

Mortality

Not a core endpoint, no data to show.

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Not a core endpoint, no data to show.

Correlations

↥

Index endpoint: PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR – Use of levodopa decarboxylase inhibitor
GWS hits:

Survival analyses between endpoints

↥

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Use of levodopa decarboxylase inhibitor

↥

Endpoint not on priority list, no data to show.